Protagonist Therapeutics (PTGX) EBIAT (2017 - 2025)
Historic EBIAT for Protagonist Therapeutics (PTGX) over the last 9 years, with Q3 2025 value amounting to -$39.3 million.
- Protagonist Therapeutics' EBIAT fell 1845.53% to -$39.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.9 million, marking a year-over-year decrease of 7312.89%. This contributed to the annual value of $275.2 million for FY2024, which is 44853.78% up from last year.
- Per Protagonist Therapeutics' latest filing, its EBIAT stood at -$39.3 million for Q3 2025, which was down 1845.53% from -$34.8 million recorded in Q2 2025.
- Protagonist Therapeutics' EBIAT's 5-year high stood at $207.3 million during Q1 2024, with a 5-year trough of -$41.0 million in Q2 2022.
- Its 5-year average for EBIAT is -$7.5 million, with a median of -$33.2 million in 2024.
- Per our database at Business Quant, Protagonist Therapeutics' EBIAT plummeted by 33545.02% in 2021 and then soared by 71479.61% in 2024.
- Protagonist Therapeutics' EBIAT (Quarter) stood at -$36.9 million in 2021, then rose by 7.35% to -$34.2 million in 2022, then skyrocketed by 179.94% to $27.3 million in 2023, then skyrocketed by 381.7% to $131.7 million in 2024, then tumbled by 129.88% to -$39.3 million in 2025.
- Its EBIAT stands at -$39.3 million for Q3 2025, versus -$34.8 million for Q2 2025 and -$11.7 million for Q1 2025.